• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NuVasive levels poaching, infringement suit against Alphatec

NuVasive levels poaching, infringement suit against Alphatec

February 15, 2018 By Fink Densford

Alphatec Spine, Nuvasive

NuVasive Inc. (NSDQ:NUVA) has filed a suit against Alphatec (NSDQ:ATEC) claiming the company hired on executives, including former COO and prez Pat Miles, with knowledge of its XLIF lateral interbody fusion procedures in an attempt to recreate the technology for its own products.

In its infringement suit, submitted this week to the U.S. District Court for the Southern District of California, San Diego-based NuVasive claims it created the XLIF method for fusing vertebral disks to reduce nerve damage and that Alphatec’s recently released devices, the Battalion lateral system, infringe on their products.

NuVasive claims that Alphatec showed interest in being acquired by NuVasive as early as January 2016, but interest was not returned. Then COO and prez Miles, who would later join Alphatec as exec chair, was noted in the court documents for turning down the opportunity to acquire Alphatec, saying it was a “waste of time as far as I am concerned.”

During his time at NuVasive, Miles is credited in inventing and creating multiple aspects of the XLIF procedure, and is named as the inventor on “at least 50 issued utility patents related to NuVasive’s XLIF procedure and systems,” according to court documents.

After divesting itself of its Globus Medical holdings in September 2016, NuVasive claims that Alphatec began to “make changes to its leadership team targeting NuVasive employees, inventors and upper level management,” according to court documents.

Miles was just one of many individuals to leave NuVasive for Alphatec, according to the filing, including inventors and upper level management the company claims were specifically targeted.

Hires from NuVasive include Alphatec’s exec chair Miles, strategic marketing and product dev exec VP Brian Snider, operations VP Mike Dendinger, posterior development VP Scott Lish and board member Quentin Blackford.

NuVasive goes on to claim that during its hiring of Snider, Alphatec stated that it he “had substantial responsibility over the anterior column business, including XLIF,” and that “we look forward to leveraging [Mr. Snider’s] energy and expertise, as we launch our new products, including Battalion Lateral,” court documents read.

NuVasive said that Alphatec leveraged this knowledge to create its new line of devices, and that it intends to continue with its development despite having taken patented technology from NuVasive.

NuVasive claims a number of infringements on its products, as well as that Alphatec willingly engaged in the infringement. The company is seeking to stop further infringement, as well as damages, including trebled damages, and other fees and costs it incurs in the suit.

The battle isn’t the first time the companies have clashed over patents and Miles. Last October, Alphatec announced a countersuit against NuVasive in response to charges levied at Miles.

Earlier that month, NuVasive filed charges against Miles, claiming that he was involved in a year-long scheme to back Alphatec and discourage NuVasive from acquiring it, in addition to breaches of contract and violations of non-compete, non-solicitation and anti-poaching clauses.

Filed Under: Legal News, Patent Infringement Tagged With: Alphatec, Nuvasive

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy